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Vagus nerve stimulation inhibits trigeminal
nociception in a rodent model of episodic migraine
Jordan L. Hawkins, Lauren E. Cornelison, Brian A. Blankenship, Paul L. Durham*
Abstract
Introduction: Although neckmuscle tension is considered a risk factor for migraine, pungent odors can act as a trigger to initiate an
attack in sensitized individuals. Although noninvasive vagus nerve stimulation (nVNS) is now an approved treatment for chronic
migraine, how it functions to inhibit trigeminal nociception in an episodic migraine model is not known.
Objectives: The objectives of this study were to determine if nVNS could inhibit trigeminal nociception in a novel model of episodic
migraine and investigate changes in the expression of proteins implicated in peripheral and central sensitization.
Methods: Sprague-Dawley male rats were injected with an inflammatory agent in the trapezius muscle before exposure to pungent
volatile compounds, which was used to initiate trigeminal nociceptor activation. The vagus nerve was stimulated transdermally by
a 1-ms pulse of 5 kHz sine waves, repeated at 25 Hz for 2minutes. Nocifensive headwithdrawal response to von Frey filaments was
determined and immunoreactive protein levels in the spinal cord and trigeminal ganglion (TG) were investigated.
Results: Exposure to the pungent odor significantly increased the number of nocifensive withdrawals in response to mechanical
stimulation of sensitized TG neurons mediated by neck muscle inflammation. Noninvasive vagus nerve stimulation inhibited
nociception and repressed elevated levels of P-ERK in TG, Iba1 in microglia, and GFAP in astrocytes from sensitized animals
exposed to the pungent odor.
Conclusion:Our findings demonstrate that nVNS inhibits mechanical nociception and represses expression of proteins associated
with peripheral and central sensitization of trigeminal neurons in a novel rodent model of episodic migraine.
Keywords: Vagus nerve stimulation, Glia, Nociception, Trigeminal, Neural modulation
1. Introduction
Migraine is a common neurological disease43 that involves
sensitization and activation of trigeminal neurons.19,54 Migraine
patients often report the presence of several risk factors that
lower the activation threshold of trigeminal nociceptive neu-
rons,25,42 including unmanaged stress and anxiety,10 which are
associated with neck muscle tension.49 Muscle tenderness and
pain are reported to have a direct relationship with chronic
migraine and frequency of episodic migraine.4,14,22,23,38 This
strong association likely involves convergence of nociceptive
neurons providing sensory innervation of neck muscles and
trigeminal nerves in the upper spinal cord.6,50,61 Thus, sustained
signaling from neck muscles could promote sensitization of
trigeminal nociceptors, lowering their activation threshold to
reported triggers such as pungent odors.8 Nassini et al.53
demonstrated that an extracted compound from leaves of the
California Bay tree, also known as the headache tree, activated
transient receptor potential ankyrin 1 (TRPA1) receptors and
mediated calcitonin gene-related peptide (CGRP) release from
trigeminal neurons. TRPA1 receptors are expressed by trigeminal
ganglion neurons that provide sensory innervation of the nasal
mucosa.52,53,62,63 Within the context of a migraine model,
exposure to a pungent odor could trigger a migraine attack in
an individual with a sensitized trigeminal nervous system
mediated by neck muscle inflammation.
There is emerging evidence that electrical stimulation of the vagus
nerve, which modulates pain transmission,56 is beneficial in the
treatment of neurological diseases including migraine and cluster
headache.30,38,39,46,59 The use of vagus nerve stimulation (VNS) has
already received FDA approval for the treatment of seizures in
refractory epilepsy and depression,48,58 and most recently for
episodic cluster headache. With respect to migraine therapy,
transdermal noninvasive VNS (nVNS) decreased the number of
headachedaysand lowered reportedpain intensity scores.38Results
from animal studies demonstrate that VNS inhibits nociceptive
signaling within the trigeminal system in models of migraine
pathology2,16,55 and orofacial pain.9,65 The inhibitory effects of VNS
on trigeminal nerves likely involve the activationof the opioid system66
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and induction of the serotonergic descending inhibition pathway.67
Release of 5-HT within the spinal cord stimulates inhibitory neurons
by the activation of 5-HT3 receptors to mediate release of the
inhibitory neurotransmitter GABA and hence decrease trigeminal
nociception.3,45,65 Vagus nerve stimulation was also reported to
decrease stimulated glutamate levels in cerebrospinal fluid in the
trigeminal nucleus caudalis in a model of migraine allodynia.55
The mechanism by which neck muscle tension contributes to
migraine pathology is not well understood, but is likely to involve
sensitization of the trigeminal system. Toward this end, we have
developed amodel of episodic migraine that involves activation of
neck muscle-mediated sensitization of trigeminal neurons by
a pungent odor. Findings from our study provide evidence that
nVNS is sufficient to inhibit trigeminal nociception and expression
of proteins associated with sensitization of trigeminal neurons in
a rodent model of episodic migraine.
2. Methods
2.1. Animals
All animal studies were conducted in agreement with approved
protocols by the Institutional Animal Care and Use Committee at
Missouri State University. Procedures were also conducted in
compliance with all guidelines established in the Animal Welfare
Act, National Institutes of Health, and ARRIVE. A concerted effort
was made to minimize the number of animals used in this study
and their suffering. On arrival, young adult male Sprague-Dawley
rats (200–300 g; Charles River, Durham, NC) were housed in
standard, clean plastic cages and allowed unrestricted access to
water and food. All animals were isolated for 1 week before the
initiation of the study to acclimate to the environment that
included a 12-hour light/dark cycle.
2.2. Muscle inflammation
Some animals (24 total) were anesthetized using 5% isoflurane by
inhalation. To induce trigeminal sensitization, complete Freund
adjuvant (CFA; Sigma-Aldrich, St. Louis, MO; 1:1 in 0.9% sterile
saline) was injected at ten different sites in the trapezius muscle
between C1 and C4 vertebras. The final volume injected was
100 mL (50 mL bilaterally) and was applied as microinjections of
10mLeach.Animalswere allowed to recover in their cages andwere
monitored for 8 days for normal grooming and feeding behaviors.
2.3. California Bay leaf exposure
To prepare the oil extract, California Bay leaves (CBL; World
Spice, Seattle, WA) were crushed and dried. The bulk, volatile oil
extract was obtained through standard steam isolation (AOAC
Official Method 962.17). From 12.5 g of leaves, approximately
1000 mL of oil was obtained, which was stored at 4˚C. Sprague-
Dawley rats (36 total) were placed in a 3.3-L box containing a tube
that was used to expose the animals to the volatile compounds in
the extracted oil. A cotton swab containing 20 mL of extracted oil
was placed in the tube such that direct contact was not possible,
and oxygen was allowed to flow through the tube for 10 minutes
at a rate of 2 L/min. After exposure to the extracted oil, animals
were returned to their normal cages.
2.4. Vagus nerve stimulation
Before exposure to the CBL extract, some animals (16 total) were
lightly anesthetized using 3% isoflurane. Noninvasive vagus nerve
stimulation was accomplished using a modified VNS device,
supplied by electroCore (Basking Ridge, NJ). The electrodes of
the stimulator were covered in electrolyte gel (electroCore) and
placed on a shaved area of the neck lateral to the trachea, parallel
to and over the vagus nerve. A 1-ms pulse of 5 kHz sine waves,
repeated at 25 Hz, for 2minutes was administered. After the initial
stimulation and electrode removal, the animals were allowed to
recover in their home cage for 2 hours before nocifensive behavior
testing. Because an inhibitory effect on mechanical nociception
was not observed after the first nVNS, which occurred before
trigeminal activation with CBL exposure, a second nerve
stimulation was delivered as described above, and 1 hour later
mechanical sensitivity was determined (Fig. 1). The control
animals were prepared in the samemanner as the nVNS animals,
except no current was applied.
2.5. Assessment of nocifensive response to
mechanical stimulation
All behavioral studies were performed between the hours of 6 AM
and 12 PM as described in previous published studies.11,17,26–28
Before testing, animals were acclimated to the Durham Animal
Holder (Ugo Basile, Varese, Italy) for 5 minutes on 3 consecutive
days. To reduce false positive responses during assessments,
animals were conditioned to a mechanical stimulus by gently
rubbing the hair follicles and epidermis located over the
cutaneous region over the eyebrowwith a pipette tip. Mechanical
nocifensive thresholds were determined in response to a series of
calibrated von Frey filaments (Stoelting, Wood Dale, IL) applied in
increasing force to the cutaneous tissue. Baseline thresholds
were determined before experimental procedures. A positive
response, which was defined by head withdrawal before the
bending of the filament, was recorded by a second researcher.
Each filament was applied 5 times, and data were reported as the
average number of responses obtained from 5 applications of
each specific calibrated filament. The 60-g filament was chosen
for additional assessment over the eyebrow region because this
force elicited an average of less than 1 response on either the right
or left side at baseline measurements for all animals (0.296 0.11
and 0.42 6 0.15, respectively). The researcher responsible for
directly testing the response to each filament was blinded to the
experimental conditions. Data are reported as the average
number of nocifensive responses to the designated force 6
SEM. Furthermore, animals that responded on average 2.5 of 5
or more times to the 60-g filament over the eyebrow region were
identified as “responders.” Animals that responded less then
these parameters were considered “non-responders.” The
percentage of responders in each group is also reported.
2.6. Tissue acquisition and processing
Spinal trigeminal nucleus (STN) and trigeminal ganglion (TG)
tissues were acquired through cranial dissection 3 hours after
exposure to the leaf extract. Animals were euthanized by CO2
asphyxiation and decapitation. Once extracted, tissues desig-
nated for immunohistochemical studies were placed in 4%
paraformaldehyde overnight at 4˚C. Samples were cryopro-
tected by placing tissues in a 12.5% sucrose solution for 1 hour
at 4˚C and then in a 25% sucrose solution overnight at 4˚C.
Samples were then mounted in Tissue-Tek Optimal Cutting
Temperature mounting media (Sakura Finetek, Torrance CA),
and 14 mm STN cross-sections and TG longitudinal sections
were obtained using a Microm HM 525 (Richard-Allen
Scientific, Kalamazoo, MI) set at 224˚C. Slices were placed
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on Fisherbrand Superfrost Plus Microscope slides (Thermo
Fischer Scientific) and stored at 220˚C.
2.7. Immunodetection and analysis
Immunostaining procedures and analysis were performed
essentially as described in previous studies.11,17,27 Slides
containing 1 tissue section from each experimental condition
were covered with 1 3 phosphate-buffered saline for 5 minutes
before incubation for 20 minutes in 5% normal donkey serum
(Jackson ImmunoResearch Laboratories, West Grove, PA) in
phosphate-buffered saline containing 0.1% Triton. Primary anti-
bodies diluted in 5% normal donkey serum and Alexa Fluor
secondary antibodies (Invitrogen; 1:200 dilution in PBS, Carls-
bad, CA) were incubated with tissues as reported in Table 1.
Tissues were mounted in the VECTASHIELD medium containing
49,6-diamidino-2-phenylindole (DAPI; Vector Laboratories,
Burlingame, CA). A Zeiss AxioCam MRm camera (Carl Zeiss,
Thornwood, NY) mounted on a Zeiss Imager Z1 fluorescence
microscope was used to collect a single 4 3 3 tiled 3200 image
of the dorsal medullary horn region and 33 3 tiled3200 images
of the V1/V2 area of the TG. Zen 2011 software (Carl Zeiss) was
used to evenly balance the background of each image before
densitometric analysis of gray scale JPEG images using ImageJ
software. For spinal cord tissues, integrated densities were
acquired from 3 independent experiments by measuring pixel
densities in 10 nonoverlapping, rectangular regions of interest
encompassing laminas I to III for each image. In addition,
background measurements, which were acquired from acellular
areas as determined by DAPI staining, were averaged and
subtracted from the regions of interest values. Relative average
mean values were determined for each condition and data were
reported as average fold change 6 SEM relative to the average
mean for control animals, which was set equal to 1. Similar
methods were used to quantitate P-ERK expression in primary
trigeminal nociceptors using background measurements ac-
quired from areas containing only Schwann cells and neural fibers
in the ganglion as determined by DAPI staining. For quantification
of nuclear P-ERK in the TG, the number of neuronal cells
exhibiting nuclear localization of P-ERK was divided by the total
number of visible neuronal nuclei as identified by DAPI staining.
Results are reported as the average percent 6 SEM of neurons
with P-ERK nuclear staining.
2.8. Statistical analysis
For nociception experiments, we anticipated a medium effect size
(h25 0.083). This study is a factorial design of 3 (Groups)3 4 (Time
points). Thesegroups includedaset of animalswithout anyadditional
experimental conditions (naive), a group involving trigeminal sensi-
tization induced by neck muscle inflammation and later activated by
an odor trigger (muscle1CBL) and a group that received both forms
of stimulation and receiving transdermal VNS (muscle 1 CBL 1
VNS). Using G-Power (Heinrich-Heine-University, Düsseldorf,
Germany) to conduct a power analysis and using a power of 0.80
ata50.05, theminimumsample size to detect expectedmain effect
and interactions required at least 24 animals (8 naive, 8 M1CBL,
8 M1CBL1VNS). Outliers were determined by SPSS Statistics 21
software (IBM,NorthCastle, NY) using 3 as amultiplier. To determine
the normality of behavioral data sets, a Shapiro-Wilk test was used,
whereas a Levene test was used to determine equal or unequal
variance. Because it was determined that data sets were in violation
of these assumptions, a nonparametric statistical analysis was used
to determine significant changes. To determine if the observed
effects were statistically significant, a Kruskal-Wallis analysis of vari-
ance (ANOVA) was performed followed by a Mann-Whitney U post
hoc testwith aBonferroni correction (aaltered50.05/3,P, 0.017) for
pairwise comparisons at each time point. In addition, a Friedman
ANOVA was performed within each group, followed by a Wilcoxon
signed-rank test with a Bonferroni correction (aaltered 5 0.05/3, P,
0.017) to evaluate comparisonsmade in a single group frombaseline
readings. All statistical tests were conducted using SPSS Statistics
software.
For the immunohistochemical studies, we anticipated a large
effect size (h25 0.702) based on previously published data.17 Using
apower of 0.80 ata50.05 alpha, theminimumsample size needed
to detect the expected main effect would require a minimum of 12
animals (4 naive, 4M1CBL, 4 M1CBL1VNS). Any values detected
as outliers by SPSS using 3 as a multiplier were removed from
analysis. A Shapiro-Wilk test was used to determine data set nor-
mality, whereas a Levene test was used to determine equal or un-
equal variance. Data sets were found to adhere to the assumption of
normality; however, not always to the assumption of equal variance.
Therefore, statistical differences were determined using a 1-way
ANOVA, supported by both Welch and Brown-Forsythe tests, with
either a Tukey or a Games-Howell post hoc test in SPSS software,
and considered different when P, 0.05.
3. Results
3.1. Repeated vagus nerve stimulation inhibited increased
nociception induced by activation of trigeminal sensitization
To evaluate the potential therapeutic use of nVNS in orofacial pain
conditions, nociceptionwas evaluated over the cutaneous area of
Figure 1. Timeline and experimental design. See text for specific details.
Table 1
Summary of primary and secondary antibodies used for
immunohistochemistry.
Antibody Host Supplier Dilution Incubation
P-ERK Rabbit Bioworld 1:500 Overnight, 4˚C
GFAP Goat Abcam 1:5,000 3 h, RT
Iba-1 Goat Abcam 1:400 3 h, RT
Alexa 488 Rabbit Life Technologies 1:200 1 h, RT
Alexa 567 Goat Life Technologies 1:200 1 h, RT
RT, room temperature.
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the eyebrow (V1) using von Frey filaments (Fig. 2). Basal
nocifensive head withdrawals were not statistically different
among the 3 groups assessed in this study in the cutaneous V1
dermatome (control: 0.38 6 0.26, 0% responders, muscle 1
CBL: 0.38 6 0.22, 0% responders, muscle 1 CBL 1 VNS: 0.31
6 0.17, 0% responders, P5 0.994). In addition, values collected
in control animals were not found to be statistically different from
their basal values (D8: 0.386 0.13, 0% responders, P5 0.527; 2
hours post CBL: 0.19 6 0.10, 0% responders, P 5 0.705; 3
hours post CBL: 0.38 6 0.20, 0% responders, P 5 0.666).
Interestingly, neck muscle inflammation on its own did not elicit
significantly different responses in the V1 dermatome as
compared to control animals 8 days after injection (control:
0.38 6 0.13, 0% responders, muscle 1 CBL: 0.50 6 0.27, 0%
responders, P5 0.505; muscle1 CBL1 VNS: 0.136 0.09, 0%
responders,P5 0.195). However, exposure of theCBL extract to
animals that received neck muscle injections exhibited a signifi-
cantly higher number of nocifensive responses as compared to
control animals (2 hours post CBL: 3.25 6 0.56, 75%
responders, P , 0.001; 3 hours post CBL: 3.13 6 0.40, 75%
responders, P5 0.005). Initially, a single treatment with nVNS did
not have a significant inhibitory effect on nocifensive responses 2
hours after CBL exposure as compared to M 1 CBL animals
(3.44 6 0.45, 87.5% responders, P 5 0.721). However, animals
treated with a second nVNS exhibited a significant decrease in
the average number of nocifensive responses 3 hours after CBL
exposure (0.63 6 0.28, 0% responders, P 5 0.005) that was
similar to the level of response for control animals (P 5 0.645).
3.2. Transdermal vagus nerve stimulation decreases
expression of P-ERK in primary afferent neurons
To begin to understand the cellular mechanisms by which nVNS
inhibits nociception, expression of P-ERK was evaluated in TG
tissues. Tissues obtained from animals subjected to both
conditions (muscle inflammation and CBL), but not receiving
treatment exhibited a significantly higher percentage of P-ERK
nuclear staining in neuronal cell bodies (38.936 5.93, P5 0.016)
when compared with control levels (Fig. 3; 14.18 6 2.18).
Similarly, in these same animals, the relative intensity value of
cytoplasmic staining for P-ERK (2.73 6 0.52, P 5 0.032) was
significantly greater than the value in control tissues (1.006 0.24).
Importantly, the percentage observed in animals that also
received nVNS was similar to the expression level determined in
control tissues (Fig. 3; nuclear: 20.71 6 5.20, P 5 0.567;
cytoplasmic: 1.79 6 0.66, P 5 0.059).
3.3. Repeated vagus nerve stimulation significantly
decreased activation of glia in the spinal trigeminal nucleus
To evaluate the effects of nVNS on glial cells in the STN,
immunohistochemical analysis was performed for GFAP,
a marker of activated astrocytes, and Iba1, a marker of activated
microglia. Animals experiencing both muscle inflammation and
CBL had significantly increased expression of Iba1 (Fig. 4; 2.976
0.40, P 5 0.007) as compared to control levels (1.00 6 0.06).
Importantly, animals that were also treated with nVNS exhibited
levels of Iba1 expression that were similar to those observed in
control tissues (Fig. 4; 1.67 6 0.39, P 5 0.360). In addition,
animals that experienced both insults without treatment demon-
strated significantly higher levels of GFAP expression (Fig. 5; 2.07
6 0.2, P 5 0.015) when compared with levels in control tissues
(1.00 6 0.14). In contrast, levels detected in animals that were
also treated with nVNS were comparable to control tissues (Fig.
5; 1.58 6 0.27, P 5 0.137).
4. Discussion
We found that nVNS significantly inhibited the nocifensive
response to mechanical stimulation of primary trigeminal neurons
in a novel rodent model of migraine pathology. In our model, neck
muscle tension/inflammation was used to promote sensitization
of trigeminal neurons that become activated on stimulation of
nasal/sinus TRPA1 receptors by the pungent stimulus derived
fromCalifornia Bay leaves (CBLs). Neckmuscle inflammationwas
chosen as a means to facilitate sensitization of the trigeminal
system because neck/shoulder tension is often cited as a risk
factor and a comorbid symptom of migraine.4,14,21,22 The
stimulus, complete Freund adjuvant, was used to induce
prolonged inflammation by eliciting a sustained immune response
for up to 2 weeks.11,26,68 The amount of adjuvant used in our
study did not negatively affect the normal feeding and eating
behavior of the animals or cause excessive grooming. However,
multiple injections of 10 mL CFA resulted in low-grade in-
flammation andmuscle tenderness that mediated sensitization of
primary trigeminal nociceptors rather than nociception, which
was observed with a single 50 mL injection (data not shown). This
sensitizing effect is likely attributable to the fact that afferent
processes of the nerves providing sensory innervation of the
muscle tissue terminate in the upper spinal cord where there is
Figure 2. Vagus nerve stimulation (VNS) inhibits trigeminal nociception to
mechanical stimuli. (A) Average number of nocifensive responses to the 60 g
filament asserted over the cutaneous eyebrow region of the face is shown.
Vertical dash arrows indicate when VNS was administered during this study.
* denotes significance from naive levels where P , 0.017, # denotes sig-
nificance from M1CBL group where P , 0.017. (B) Representation of the
percentage of responders to the 60 g filament applied over the V1 dermatome.
CBL, California Bay leaf.
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convergence with the trigeminal system.5,6,50 To cause activation
of sensitized trigeminal nociceptive neurons, we used an oil
extract containing volatile, stimulatory chemicals that was
prepared from the leaves of the California Bay tree. The rationale
for choosing this type of stimulus was based on pungent odors
being a reported migraine trigger,35 and the seminal work by
Nassini et al. that demonstrated application of umbellulone,
a chemical isolated from CBL, could elicit a nocifensive trigeminal
response on topical application of this compound to the nasal
mucosa.53 In addition, umbellulone was shown to cause
activation of the TRPA1 receptors expressed on trigeminal
neurons and mediate the release of CGRP, a molecule strongly
implicated in migraine pathology.7 Our goal was to develop
a clinically relevant rodent migraine model that involved inducing
or triggering trigeminal activation without having to directly apply
or inject the stimulus, and hence why we chose to expose the
animals to volatile compounds by inhalation, a more natural and
less-invasive process. It should be noted that trigeminal
nociceptor activationwas induced on activation of V1/V2 neurons
that provide sensory innervation of the nasal and sinus
mucosa,62,63 which led to an enhanced nocifensive response in
V1 (eyebrow) neurons. Taken together, results from our rodent
model mimic several key features of episodic migraine pathology
including increased mechanical nociception and temporally
correlated changes in the expression of several proteins
implicated in peripheral and central sensitization.
After the activation of trigeminal neurons, as determined by
an increase in nocifensive withdrawal response from mechan-
ical stimulation, elevated levels of the active, phosphorylated
form of the MAP kinase P-ERK were observed primarily in
trigeminal neurons in the V1/V2 regions of the ganglion.
Increased P-ERK was seen in the cytoplasm and nucleus of
both larger A-delta and smaller diameter C fiber neuronal cell
bodies. P-ERK is regarded as a marker of activated nocicep-
tive neurons by promoting cellular changes implicated in
excitation and release of inflammatory mediators.32 For
example, elevated P-ERK levels in the cytoplasm could
mediate increased secretion by phosphorylation of ion
channels and proteins involved in vesicle docking, fusion,
and neuropeptide release.1 In addition, enhanced nuclear
expression of P-ERK could lead to stimulation of promoter
activity and thus contribute to the production of neuropeptides
such as CGRP20 and other known MAP-kinase–responsive
genes including cytokines and nitric oxide.24,29,37 Increased
Figure 3. Stimulated P-ERK expression is repressed by vagus nerve stimulation (VNS). The percentage of P-ERK positive neurons and relative expression of
cytoplasmic P-ERK was significantly increased in the V1/V2 region of the trigeminal ganglion in response to muscle inflammation and California Bay leaf (CBL).
The stimulatory effect was inhibited by VNS. Representative3200 images taken in V1/V2 regions of the trigeminal ganglion depicting DAPI and P-ERK staining in
naive, M1CBL, andM1CBL1VNS samples taken 3 hours after CBL exposure. Scale bar5 100mm.Blue boxes placed in P-ERK images indicate areas that were
selected for enlarged images in the third and fourth columns. The table below the images summarizes the average percentage of positive labeled neurons6 SEM
exhibiting nuclear localization and the change in relative intensity of P-ERK staining in the cytoplasm. * denotes significance from naive levels where P , 0.05.
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expression and release of inflammatory mediators from the
neuronal cell body would stimulate satellite glial cells that
function to modulate the excitability state of the neurons.40,64
In addition to cellular changes within the ganglion, activation of
sensitized trigeminal neurons by a pungent odor resulted in
enhanced expression of proteins associated with activated
astrocytes (GFAP) and microglia (Iba1) within the upper spinal
cord.33 Elevated levels of these proteins in glial cells, in con-
junction with changes in second order neurons, are known to
play an important role in the development and maintenance of
central sensitization,18,31 which is a pathophysiological event
reported in migraine that contributes to enhanced pain sen-
sation (hyperalgesia) and allodynia.19 Interestingly, activated
astrocytes in the dorsal medullary horn are involved in D-serine
modulation of NMDAR activity and mechanical allodynia.47
Thus, the activation of sensitized trigeminal neurons leads to
changes in neurons in the ganglion and glial cells in the spinal
cord, which temporally correlate with increased trigeminal
nociception.
A major finding from our study was that nVNS was sufficient
to significantly inhibit nocifensive head withdrawal response
from mechanical stimulation of V1 trigeminal nociceptors. Our
finding is similar to the results from other studies in which VNS
inhibited trigeminal activation in novel models involving tri-
geminal allodynia, primary headache, and cortical spreading
depression.2,16,55 Interestingly, a single nVNS before trigem-
inal activation did not block the nocifensive response to the
pungent odor in our study. This finding is similar to the reported
effect of the antimigraine triptan drugs, which are most
effective when administered at the onset of trigeminal
activation. In agreement with the change in nociception, nVNS
resulted in an inhibitory effect on the expression of proteins
associated with peripheral and central sensitization. The
elevated level of P-ERK expression in the cytoplasm and
nucleus of trigeminal neurons was significantly inhibited by
nVNS as were the elevated levels of Iba1 and GFAP. Thus,
nVNS seems to function at multiple levels within the trigeminal
system to repress the activation of sensitized primary tri-
geminal neurons and repress the activation of microglia and
astrocytes. The exact mechanism by which nVNS modulates
nociception and regulates protein expression in our model is
not known but may involve increased expression of IL-10 and
MAP kinase phosphatases in the TG, activation of the
descending inhibitory pathway, and suppression of glia
activation. In support of a possible role for IL-10 in mediating
the inhibitory effects of nVNS on P-ERK levels, VNS has been
shown to cause an increase in peripheral levels of the anti-
inflammatory cytokine IL-10.44 Elevated levels of IL-10 could
suppress the stimulatory effects of proinflammatory cytokines
on P-ERK expression36 in the TG to inhibit trigeminal
sensitization and activation.15 Given the key role of MAP
kinase phosphatases (MKPs) in regulating activity of the MAP
kinases including ERK,34,60 increased levels of the phospha-
tases MKP-1 and MKP-3 are candidates for
Figure 4. Levels of Iba1 inmicroglia were repressed by vagus nerve stimulation (VNS). Representative3200 images taken in laminas I to III of themedullary horn in
the upper spinal cord depicting DAPI and Iba1 staining in naive,M1CBL, andM1CBL1VNS samples taken 3 hours after California Bay leaf (CBL) exposure. Scale
bar5 100mm.Blue boxes placed in Iba1 images indicate areas that were selected for enlarged images in the third and fourth columns. The table below the images
summarizes the average fold change6 SEM as compared to levels detected in naive samples, in which the mean value was set equal to 1. * denotes significance
from naive levels where P , 0.05.
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dephosphorylation and hence decreasing ERK levels. We have
previously reported that increased levels of MKP-1 are
associated with the inhibition of stimulated expression of
signaling proteins in trigeminal neurons and satellite glial
cells.12,13 Enhanced descendingmodulationmediated by VNS
could lead to increased release of the inhibitory neurotrans-
mitter GABA and inhibition of second-order nociceptive
neurons, astrocytes, and microglia.41,56 Although evidence
for direct activation of this pathway was not demonstrated in
our study, enhanced descending modulation provides a pos-
sible mechanism to help explain the inhibitory effects of VNS in
the STN on glial cell activation.51,57
In summary, results fromour study provide evidence that nVNS
can inhibit nociception and cellular changes associated with
peripheral and central sensitization in a novel rodent model of
episodic migraine. Future studies will focus on determining the
mechanism of action of nVNS and optimizing the temporal
parameters required to achieve maximum inhibitory effects of the
trigeminal system.
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